Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ATM | Q13315 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28432086 | 0.91 | MMP12 (0.47) | MMP12KDM4EATMHTTCYP19A1 | |
| SCHEMBL8773544 | 0.89 | MMP12 (0.49) | MMP12KDM4EATMHTTCYP19A1 | |
| SCHEMBL28426296 | 0.88 | CYP19A1 (0.49) | MMP12KDM4EATMHTTCYP19A1 | |
| SCHEMBL10962514 | 0.85 | MMP12 (0.46) | MMP12KDM4EATMHTTCYP19A1 | |
| SCHEMBL2056164 | 0.84 | MAOB (0.54) | MMP12KDM4ECYP19A1KMT2AMEN1 | |
| SCHEMBL68886 | 0.81 | RAB9A (0.51) | MMP12KDM4EATMHTTCYP19A1 | |
| SCHEMBL2760390 | 0.78 | ALDH1A1 (0.54) | MMP12KDM4ECYP19A1KMT2ARAB9A | |
| SCHEMBL10977113 | 0.78 | METAP1 (0.53) | MMP12KDM4EATMHTTCYP19A1 | |
| SCHEMBL5539912 | 0.78 | HSD17B10 (0.45) | MMP12KDM4EKMT2ARAB9AMEN1 | |
| SCHEMBL7476730 | 0.77 | MMP12 (0.66) | MMP12KDM4ECYP19A1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
| CN-111100101-B | Catalytic synthesis method of 3-benzofuranone compounds | 浙江万里学院 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021003295-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| CN-111100101-A | Catalytic synthesis method of 3-benzofuranone compounds | 浙江万里学院 | 2020-05-05 | — | — | CN | disclosed |
| US-20170334923-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-11-23 | — | — | US | disclosed |
| US-9488914-B2 | Fluorine-containing sulfonic acid salt, fluorine-containing sulfonic acid salt resin, resist composition, and pattern forming method using same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9488914-B2 | Fluorine-containing sulfonic acid salt, fluorine-containing sulfonic acid salt resin, resist composition, and pattern forming method using same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9211725-B2 | Inkjet recording method and printed material | FUJIFILM CORPORATION (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150198879-A1 | Fluorine-Containing Sulfonic Acid Salt, Fluorine-Containing Sulfonic Acid Salt Resin, Resist Composition, and Pattern Forming Method Using Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-07-16 | — | — | US | disclosed |
| WO-2013111667-A1 | FLUORINE-CONTAINING SULFONIC ACID SALT, FLUORINE-CONTAINING SULFONIC ACID SALT RESIN, RESIST COMPOSITION, AND PATTERN FORMING METHOD USING SAME | セントラル硝子株式会社 (JP) | 2013-08-01 | — | — | WO | disclosed |
| US-20120059053-A1 | COMPOUNDS OF 2,3-DIHYDRO-BENZOFURAN | FERRER INTERNATIONAL, S.A. (ES) | 2012-03-08 | — | — | US | disclosed |
| CN-1154646-C | As α2Benzisoxazoles and phenones as antagonists | ղɭҩҵ����˾ | 2004-06-23 | — | — | CN | disclosed |
| EP-1140934-B1 | BENZISOXAZOLES AND PHENONES AS ALPHA-2-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-08 | — | — | EP | disclosed |
| US-6576640-B1 | Rapidly penetration into central nervous system; treating noradrenaline deficiency; depression, Parkinson's disease | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-06-10 | — | — | US | disclosed |
| EP-1119571-B1 | TRICYCLIC DELTA3-PIPERIDINES AS ALPHA2-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2003-02-19 | — | — | EP | disclosed |
| US-6495555-B1 | CENTRAL ALPHA2-ADRENOCEPTOR ANTAGONISTS; DEPRESSION; PARKINSON'S DISEASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-12-17 | — | — | US | disclosed |
| CN-1331692-A | Benzisozazoles and phenones as alpha antagonist | JANSSEN PHARMACEUTICA NV (BE) | 2002-01-16 | — | — | CN | disclosed |
| EP-1140934-A1 | BENZISOXAZOLES AND PHENONES AS $g(a) 2?-ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037466-A1 | BENZISOXAZOLES AND PHENONES AS α2-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059053-A1 | COMPOUNDS OF 2,3-DIHYDRO-BENZOFURAN | MTNR1A, MTNR1B, CRY2 | MMP12 2930/4885KDM4E 958/4885ATM 3975/4885 |
| US-20170334923-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | MMP12 3284/4885KDM4E 1197/4885ATM 4625/4885 |
| US-20150198879-A1 | Fluorine-Containing Sulfonic Acid Salt, Fluorine-Containing Sulfonic Acid Salt Resin, Resist Composition, and Pattern Forming Method Using Same | RER1, SMARCC1, SMCHD1 | MMP12 3525/4885KDM4E 2052/4885ATM 3777/4885 |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | MMP12 3634/4885KDM4E 1372/4885ATM 4707/4885 |
| US-11840541-B2 | Opioid receptor modulators | OPRM1, OPRL1, OPRD1 | MMP12 3284/4885KDM4E 1197/4885ATM 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.